Nature Reviews Cancer contents February 2018 Volume 18 Number 2 65-134

If you are unable to see the message below, click here to view.
 

Advertisement
npj Breast Cancer: Now included in PubMed Central   npj Breast Cancer is an online-only, open access, multidisciplinary journal dedicated to publishing high-quality original research articles, reviews, editorials, commentaries, and hypothesis generating observations on all areas of breast cancer research. All content from the journal is now included in PubMed Central and PubMed. Part of the Nature Partner Journal series, published in partnership with the Breast Cancer Research Foundation.   Explore all articles here >>>
TABLE OF CONTENTS
February 2018 Volume 18 Number 2
2016 2-year Impact Factor 37.147 Journal Metrics 2-year Median 28	In this issue Research Highlights Reviews Perspectives   Also this month  Featured article: Targeting mutant p53 for efficient cancer therapy Vladimir J. N. Bykov, Sofi E. Eriksson, Julie Bianchi & Klas G. Wiman
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Frontiers in Cancer Immunotherapy  April 26-27, 2018 Keynote speakers Jeffrey Ravetch of The Rockefeller University and Miriam Merad of Mount Sinai School of Medicine join other top experts in oncology and immunology to discuss emerging approaches and challenges faced in this rapidly evolving field. Abstract deadline: Feb. 23rd. Find more information and register here.
Advertisement
Nature Outlook: Cancer immunotherapy  Drugs that mobilize our immune systems against cancer are dramatically improving care for many people, and research is rapidly moving ahead in the lab and the clinic.  Access this Outlook free >> Produced with support from  F. Hoffmann-La Roche Ltd Medimmune  Produced with support of a grant from Merck & Co., Inc.
Advertisement
nature.com webcasts Springer Nature presents a custom webcast on: Applications of imaging flow cytometry for the diagnosis of leukaemia Date: Thursday, February 22, 2018 Time: 8AM PST | 11AM EST | 4PM GMT | 5PM CEST Register for the webcast and live Q&A session Sponsored by:  MilliporeSigma
RESEARCH HIGHLIGHTS   Top Tumour microenvironment: Radical changes p65 | doi:10.1038/nrc.2018.4 Reactive oxygen species derived from inflammatory myeloid cells is sufficient to induce mutagenesis in intestinal epithelial cells, independently of cytokines, to promote tumour initiation and progression. PDF Metabolism: Fusion power p66 | doi:10.1038/nrc.2018.2 The fusion gene consisting of fibroblast growth factor receptor 3 and transforming acidic coiled-coil-containing protein 3 is oncogenic and present in a small cancer subset. Frattini et al. have identified that this fusion gene drives peroxisomal and mitochondrial biogenesis. PDF Oncogenes: Driving immune evasion p67 | doi:10.1038/nrc.2018.5 Three recent papers have shed light on how the common oncogenic drivers MYC and RAS can induce an immunosuppressive tumour microenvironment. PDF   IN BRIEF Immunotherapy: Bad B cells | Tumour metabolism: The promoter becomes the suppressor | Gastric cancer: Risk analysis PDF Nature Reviews Cancer JOBS of the week Faculty Positions in Translational Sensory Neuroscience and Cancer Creighton University School of Medicine, Department of Biomedical Sciences Associate Director, Population Science (Cancer) The Stanford Cancer Institute Post Doctoral Researcher The Ohio State University Comprehensive Cancer Center and Colleage of Medicine Postdoctoral Scientist in Oncology Johnson & Johnson Pharmaceutical Research & Development Patient Specific iPS Cells for Studying Leukemia Institute for Biomedical Engineering, Department of Cell Biology More Science jobs from Nature Reviews Cancer EVENT 4th World Congress on Cancer and Prevention Methods 19.04.18 Valencia, Spain More science events from
Advertisement
Do you have a career question?  The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. Listen today!
REVIEWS		Top
Ubiquitin ligases in oncogenic transformation and cancer therapy Daniela Senft, Jianfei Qi & Ze'ev A. Ronai p69 | doi:10.1038/nrc.2017.105 Ubiquitin ligases (E3s) participate in many cellular processes, including cell cycle progression and cell death. This Review by Senft et al. discusses how deregulation of E3s can lead to tumorigenesis and highlights the opportunities for targeting E3s as an anticancer therapy. Abstract | Full Text | PDF | Supplementary information
Targeting mutant p53 for efficient cancer therapy Vladimir J. N. Bykov, Sofi E. Eriksson, Julie Bianchi & Klas G. Wiman p89 | doi:10.1038/nrc.2017.109 Inactivating mutations in the tumour suppressor gene TP53 are frequent in cancer. This Review provides a critical overview of reactivating p53 as a therapeutic strategy, describing preclinical and clinical compounds that re-establish the functions of wild-type p53 in tumours. Abstract | Full Text | PDF
Advertisement
Nature Outlook: Bladder cancer  After three decades without progress, there is now hope that we can move the needle on treating bladder cancer.  Access the free Outlook >>  Produced with support from:  AstraZeneca
PERSPECTIVES		Top
OPINION Autoimmunity checkpoints as therapeutic targets in B cell malignancies Markus Muschen p103 | doi:10.1038/nrc.2017.111 Recent studies have suggested that autoimmunity checkpoints (AICs) are fully functional in B cell leukaemias and lymphomas, despite malignant transformation. This Opinion article proposes that targeted engagement of AICs might represent a therapeutic opportunity to overcome drug resistance in B cell malignancies. Abstract | Full Text | PDF
OPINION Differentiation therapy revisited Hugues de The p117 | doi:10.1038/nrc.2017.103 Differentiation therapy has shown great success in the treatment of acute promyelocytic leukaemia (APL). This Opinion article discusses the molecular basis for the success of APL treatment and the potential of drug-induced tumour cell differentiation in other malignancies. Abstract | Full Text | PDF
VIEWPOINT EMT in cancer Thomas Brabletz, Raghu Kalluri, M. Angela Nieto & Robert A. Weinberg p128 | doi:10.1038/nrc.2017.118 In this Viewpoint article, we asked four scientists working in the field of epithelial to mesenchymal transition (EMT) to provide their opinions on the role of this complicated phenomenon in cancer biology as well as the challenges of this fast-moving field and the directions it should take in the future. Abstract | Full Text | PDF
Corrigendum: Ribosome biogenesis in cancer: new players and therapeutic avenues Joffrey Pelletier, George Thomas & Sinisa Volarevic p134 | doi:10.1038/nrc.2018.3 Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.